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Abstract
Impaired endogenous fibrinolysis is novel biomarker that can identify patients with ACS at increased cardiovascular risk. The 
addition of Very Low Dose Rivaroxaban (VLDR) to dual antiplatelet therapy has been shown to reduce cardiovascular events 
but at a cost of increased bleeding and is therefore not suitable for all-comers. Targeted additional pharmacotherapy with 
VLDR to improve endogenous fibrinolysis may improve outcomes in high-risk patients, whilst avoiding unnecessary bleeding 
in low-risk individuals. The VaLiDate-R study (ClinicalTrials.gov Identifier: NCT03775746, EudraCT: 2018-003299-11) 
is an investigator-initiated, randomised, open-label, single centre trial comparing the effect of 3 antithrombotic regimens on 
endogenous fibrinolysis in 150 patients with ACS. Subjects whose screening blood test shows impaired fibrinolytic status 
(lysis time > 2000s), will be randomised to one of 3 treatment arms in a 1:1:1 ratio: clopidogrel 75 mg daily (Group 1); 
clopidogrel 75 mg daily plus rivaroxaban 2.5 mg twice daily (Group 2); ticagrelor 90 mg twice daily (Group 3), in addition 
to aspirin 75 mg daily. Rivaroxaban will be given for 30 days. Fibrinolytic status will be assessed during admission and at 2, 
4 and 8 weeks. The primary outcome measure is the change in fibrinolysis time from admission to 4 weeks follow-up, using 
the Global Thrombosis Test. If VLDR can improve endogenous fibrinolysis in ACS, future large-scale studies would be 
required to assess whether targeted use of VLDR in patients with ACS and impaired fibrinolysis can translate into improved 
clinical outcomes, with reduction in major adverse cardiovascular events in this high-risk cohort.
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Abbreviations
ACS  Acute coronary syndrome
DAPT  Dual antiplatelet therapy
GTT  Global thrombosis test
LT  Lysis time
MACE  Major adverse cardiovascular event
NSTEMI  Non ST-segment elevation myocardial 
infarction
OT  Occlusion time
PPCI  Primary percutaneous coronary intervention
STEMI  ST-segment elevation myocardial infarction
TEG  Thromboelastography
VLDR  Very Low Dose Rivaroxaban
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• Impaired endogenous fibrinolysis is a novel, independent 
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• Pharmacological modulation of endogenous fibrinolysis 
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• The VaLiDate-R study will assess whether addition of 
low dose rivaroxaban to dual antiplatelet therapy can 
enhance endogenous fibrinolysis in ACS.
Background
Antithrombotic treatment for acute coronary syndrome 
(ACS) beyond the acute admission, consists of dual anti-
platelet therapy, comprising of aspirin together with a  P2Y12 
inhibitor [1, 2]. Following the results of the CURE study 
showing the benefits of adding the  P2Y12 inhibitor clopi-
dogrel to aspirin in patients with ACS [3], more potent 
 P2Y12 inhibitors ticagrelor [4] and prasugrel [5], showed fur-
ther reduction of ischaemic events compared to clopidogrel, 
albeit at the expense of higher bleeding risks. Beyond dual 
antiplatelet therapy (DAPT), trials have explored the con-
cept of using triple (rather than dual) antithrombotic therapy 
to further reduce ischaemic events following ACS [6] with 
the addition to DAPT of cilostazol [7], vorapaxar [8], rivar-
oxaban [9] and dabigatran [10]. This has shown that whilst 
this approach can reduce recurrent ischaemic events, it sig-
nificantly increases the risk of bleeding and therefore is not 
suitable for every patient [6].
Identification of patients at increased risk of future 
adverse thrombotic events would be highly desirable, since 
this group could be targeted with more potent antithrom-
botic medications, allowing use of less potent medications 
in low-risk groups to reduce bleeding and thereby increas-
ing the net clinical benefit. Ideally, such therapy should be 
personalized to the individual, to achieve the greatest benefit 
at the lowest risk for the population. In order to offer per-
sonalized antithrombotic therapy, it is necessary to iden-
tify which patients remain prothrombotic, and at increased 
ischaemic risk, despite treatment with dual antiplatelet 
therapy (DAPT).
Following the onset of a thrombotic stimulus such as rup-
ture or erosion of a thin-cap fibroatheroma, the likelihood of 
ACS and potential coronary occlusion is determined by the 
overall balance between factors which propagate thrombosis, 
mainly through enhanced platelet aggregation and activa-
tion of the coagulation cascade, and the effectiveness of the 
inherent defence mechanism of endogenous thrombolysis/
fibrinolysis.
Whilst treatment with DAPT addresses the enhanced 
platelet reactivity in ACS, ongoing activation of the coagu-
lation cascade and impaired endogenous fibrinolysis are 
unaffected by current DAPT. There is increasing evidence 
that impaired endogenous fibrinolysis is a strong predic-
tor of residual cardiovascular risk in patients with ACS. 
Altered fibrin clot structure and increased resistance of the 
clot to lysis have been associate with myocardial infarction 
and stent thrombosis [11–14]. In the last 2 years, two large 
prospective studies have confirmed that impaired fibrinol-
ysis in patients with ACS is a novel independent marker 
of increased cardiovascular risk [15, 16]. In a sub-study 
of > 4000 patients in the PLATO trial, assessment of fibrin 
clot lysis using a validated turbidimetric assay revealed that 
impaired fibrin clot lysis was an independent predictor of 
adverse outcome in ACS [15]. After adjusting for estab-
lished cardiovascular risk factors, each 50% increase in lysis 
time was associated with cardiovascular death/spontaneous 
MI [Hazard ratio [HR] 1.17, 95% confidence interval (CI) 
1.05–1.31; p < 0.01] and cardiovascular death alone [HR 
1.36, 95% CI 1.17–1.59; p < 0.001]. Earlier work employ-
ing a point-of-care assay of whole blood fibrinolysis showed 
that some 23% of patients with non ST-segment elevation 
myocardial infarction (NSTEMI) exhibit impaired endog-
enous fibrinolysis (lysis time, LT ≥ 3000 s) despite DAPT, 
and this is predictive of recurrent adverse cardiovascular 
events [HR: 2.52, p < 0.04] and cardiovascular death [HR: 
4.2, p = 0.033] over the subsequent year. with hazard increas-
ing with increasing lysis time [17]. More recently, the RISK 
PPCI study from our group, involving nearly 500 patients 
with ST-segment elevation myocardial infarction (STEMI) 
showed that impaired endogenous fibrinolysis (LT ≥ 2500 s) 
detected in 14% patients on admission was strongly related 
to recurrent major cardiovascular events (HR 9.1, 95% CI 
4.28–15.03, p = 0.001), driven by cardiovascular death and 
myocardial infarction [16].
Pharmacological modulation of endogenous 
fibrinolysis
Unlike the enhanced platelet reactivity in these patients 
which reduced from admission to discharge, presumably 
reflecting the onset of effect of antiplatelet therapy, fibrinoly-
sis in ACS patients appears unaffected by DAPT [15, 16]. 
Our group has previously investigated the effects of  P2Y12 
inhibitors on endogenous fibrinolysis and shown that these 
agents appear to have minimal impact on fibrinolysis [18]. 
In a small study, compared to baseline tests performed in 
the absence of anticoagulation, treatment with non-vita-
min K antagonist oral anticoagulation appeared to favour-
ably enhance endogenous fibrinolysis [19]. This finding 
is supported by the results of the ATLAS ACS-2 TIMI 51 
study, showing that addition of very low-dose rivaroxaban 
2.5 mg twice daily to DAPT in ACS patients significantly 
reduced the primary efficacy end point of the composite of 
death from cardiovascular causes, myocardial infarction, or 
stroke compared to placebo (9.1% vs. 10.7%, P = 0.02) but 
increased the risk of major bleeding and intracranial haem-
orrhage [9]. In individuals with stable cardiac or vascular 
disease, the COMPASS study demonstrated the benefit 
of Very Low Dose Rivaroxaban in addition to aspirin in 
reducing the composite of cardiovascular death, stroke, or 
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myocardial infarction (4.1 vs. 5.4%, P < 0.001) albeit at a 
cost of increased bleeding [20].
Study rationale
Measurement of endogenous fibrinolysis appears to identify 
patients who, despite DAPT, are at increased risk of recur-
rent adverse cardiovascular events. Additional pharmaco-
therapy to improve endogenous fibrinolysis may improve 
outcomes in high risk patients, whilst avoiding unneces-
sary additional pharmacotherapy and bleeding in low risk 
patients.
Hypothesis
We hypothesize that in patients with ACS who demon-
strate impaired fibrinolysis, use of Very Low Dose Rivar-
oxaban (VLDR), targeting the thrombin pathway, in addi-
tion to DAPT, will result in improved fibrinolytic profile, 
compared to patients taking DAPT alone.
Methods
Study principle and population
The VaLiDate-R study (ClinicalTrials.gov Identifier: 
NCT03775746, EudraCT: 2018-003299-11) is an investi-
gator-initiated, randomised, open-label, single centre trial 
comparing the effects of ticagrelor, clopidogrel and clopi-
dogrel combined with Very Low Dose Rivaroxaban on 
fibrinolytic status in patients with ACS. Patients admitted to 
hospital with ACS (including those with STEMI, NSTEMI 
and unstable angina) who fulfil the inclusion and exclusion 
criteria of the study will be eligible for inclusion.
The main objective of the study is to investigate the 
impact these pharmacotherapies on fibrinolytic status in 
patients with ACS.
Table 1  VaLiDate-R inclusion/exclusion criteria
Inclusion Exclusion
1. Male and female patients aged 18 years or over
2. Have a diagnosis of acute coronary syndrome requiring treatment 
with dual antiplatelet therapy
3. Be willing and able to understand the Participant Information Sheet 
and provide informed consent
4. Agree to comply with the drawing of blood samples for the assess-
ments
5. Not meet any of the exclusion criteria
1. Male and female participants aged < 18 years of age
2. Patient unwilling or unable to give informed consent
3. Patients who might be pregnant or are breast-feeding
4. Active clinically significant bleeding
5. Patient who, in the opinion of the investigator, has condition con-
sidered to be a significant risk for major bleeding (such as current or 
recent gastrointestinal ulceration, presence of malignant neoplasm 
at high risk of bleeding, recent brain or spinal injury, recent brain, 
spinal or ophthalmic surgery, recent intracranial haemorrhage, known 
or suspected oesophageal varices, arteriovenous malformations, 
vascular aneurysms or major intraspinal or intracerebral vascular 
abnormalities)
6. Hepatic disease associated with coagulopathy and clinically relevant 
bleeding risk including cirrhotic patients with Child Pugh B and C
7. Patient with any contraindications to use of antiplatelet agents or 
anticoagulants
8. Hypersensitivity to the active substance or to any of the excipients 
listed in Summary of Product Characteristics (SmPC) of Rivaroxaban
9. Concomitant treatment with any other anticoagulants e.g. unfraction-
ated heparin (UFH), low molecular weight heparins (enoxaparin, 
dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral antico-
agulants (warfarin, dabigatran etexilate, apixaban etc.) except under 
specific circumstances of switching anticoagulant therapy or when 
UFH is given at doses necessary to maintain an open central venous 
or arterial catheter
10. Concomitant treatment of ACS with antiplatelet therapy in patients 
with a prior stroke or a transient ischaemic attack (TIA)
11. Patient with ongoing active alcohol or substance abuse or demon-
strates signs or clinical features of active substance abuse
12. Patient with any major bleeding diathesis or blood dyscrasia at 
baseline (platelets < 70 × 109/l, Hb < 80 g/l, INR > 1.4, APTT > x 
2UNL, leucocyte count < 3.5 × 109/l, neutrophil count < 1 × 109/l)
13. Patient currently enrolled in an investigational drug trial
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Inclusion and exclusion criteria
The VaLiDate-R study is an all-comers clinical trial enroll-
ing patients presenting with ACS who meet the inclusion 
and exclusion criteria as set out in Table 1.
A two-stage consent process is adopted where an eligible 
patient will first consent to a screening blood test to iden-
tify impaired endogenous fibrinolysis before proceeding to a 
full consent to allow for randomisation and trial procedures. 
In cases of patients presenting acutely to the hospital with 
STEMI for PPCI, a delayed consent approach is undertaken, 
with ethical permission, whereby screening blood tests for 
assessment of thrombotic status are taken at the same time 
as standard of care blood samples on arrival, and patients 
are consented for the study after the PPCI procedure when 
they are stable and able to carefully consider the study. This 
is to ensure the consent process is fully informed (patients 
presenting with STEMI are unwell and often haemodynami-
cally unstable, thus may not be in a suitable state to give 
full informed consent) and does not impact on the clinical 
care (explaining the study and obtaining full consent might 
cause delay to the emergency PPCI procedure) whilst not 
compromising the integrity of the sampling process (drugs 
such as heparin given during the procedure may affect the 
thrombotic status of patients). If after the emergency pro-
cedure the patient declines to participate or is unable to 
consent, the patient will not be included in the study. This 
will be recorded as a screen-fail. However, if the patient 
consents after the procedure, clinical information will be 
double checked to determine eligibility. If the thrombotic 
status is impaired and he/she fits the study criteria, written 
full informed consent will be obtained.
Randomisation and study groups
Allocation of patients to one of the three study groups will 
be made by the use of a web-based block randomisation 
process. In subjects whose screening blood test shows that 
fibrinolytic status is impaired (LT > 2000 s), full written 
informed consent will be obtained, and patients will be ran-
domised to one of 3 treatment arms in a 1:1:1 ratio: clopi-
dogrel 75 mg daily (Group 1); clopidogrel 75 mg daily plus 
rivaroxaban 2.5 mg twice daily (Group 2); ticagrelor 90 mg 
twice daily (Group 3), in addition to standard therapy with 
aspirin 75 mg daily. For patients randomised to a new drug, 
for example patients initially treated with ticagrelor who are 
subsequently randomised to clopidogrel, a loading dose of 
the new medication will be given (clopidogrel 300 mg or 
ticagrelor 180 mg). The duration of rivaroxaban is 30 days 
after which the patient will stop rivaroxaban and will con-
tinue clopidogrel only or be switched to ticagrelor (including 
with loading), as decided by the clinical care team. Dura-
tion of  P2Y12 inhibitor treatment will be determined by the 
clinical care team. All other treatments will be continued 
in accordance with standard of care, at the discretion of the 
clinical team.
Admission 
with ACS
Screening
Lysis 
Time 
≥2000s
Clopidogrel 
75mg o.d. +
Rivaroxaban 
2.5mg b.i.d.
Clopidogrel 
75mg o.d.
6 months
Visit 2 
(Week 2)
Assessment 
of 
fibrinolyc 
status, 
adverse 
events and 
drug 
compliance
Telephonic
follow-up 
(6 months)
Assessment of 
adverse events
Rivaroxaban 
disconnued  
day 30
Acute Admission Study drug
Ticagrelor 90mg 
b.i.d.
Discharge
Visit 3 
(Week 4)
Assessment 
of 
fibrinolyc 
status, 
adverse 
events and 
drug 
compliance
Visit 4 
(Week 8)
Assessment 
of 
fibrinolyc 
status, 
adverse 
events and 
drug 
compliance
Day 30
Lysis 
Time 
<2000s
Excluded
Study end
Randomize
Fig. 1  Outline of study and follow-up procedure
Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet…
1 3
Study follow up
Patients will return for assessment and blood draw at 
2 weeks, 4 weeks and 8 weeks to assess fibrinolytic status, 
record any adverse events and evaluate compliance. At each 
visit, subjects will be asked about compliance and asked 
to return any unused medication. Additionally, patients in 
the rivaroxaban arm will have Factor Xa levels assessed to 
confirm compliance during Visit 2 and 4, taken during the 
peak effect of rivaroxaban (between 2 and 5 h post-dose). A 
telephonic follow up will be performed at 6 months to assess 
for further clinical events. Figure 1 summarises the study 
flow and follow up procedures.
Study related procedures
A single blood draw will be used for tests of thrombosis 
and thrombolysis. The first 10 ml blood will be used for 
the Global Thrombosis Test (GTT) assay and thromboelas-
tography (TEG), and citrated plasma stored at − 80 ºC for 
subsequent analysis.
Global thrombosis test
The Global Thrombosis Test (GTT) (Thromboquest Lim-
ited, London, UK) is point-of-care test of thrombotic sta-
tus that utilises native (non-anticoagulated) blood to assess 
thrombosis (occlusion time) and thrombolysis (lysis time). 
A 4 ml blood sample is introduced into the cartridge and 
the measurement is fully automated. Blood flows under the 
influence of gravity at 37 °C, and is exposed to high shear 
stress, resulting in platelet activation. Further downstream, 
low shear and turbulent flow favours large platelet aggre-
gate formation leading to the generation of thrombin and 
onset of thrombosis. Flow then carries these fibrin-coated 
platelet aggregates downstream leading to thrombotic occlu-
sion. Downstream, a light-interruption sensor detects the 
blood drops: the instrument measures the time between two 
consecutive drops (d). At a predefined point (d ≥ 15 s) the 
occlusion time (OT, s) is detected.  After a 15 s stabilisation 
period, during which the light sensor is inactive, the instru-
ment detects restart of flow due to endogenous fibrinolysis 
and this is recorded as the lysis time (LT, s).
Thromboelastography
Thromboelastography (TEG, Haemonetics Corporation, 
USA) is point-of-care technique measuring the viscoelastic 
properties of blood as it clots under low shear stress based 
on pin-and-cup technology. Whole blood is placed in the 
cup which oscillates 4° 45′ every 5 s while a pin on a torsion 
wire is suspended in the blood. As the viscoelastic strength 
of the clot increases, more rotation is transmitted to the tor-
sion wire and is detected by an electromagnetic transducer. 
The kinetic changes during clot formation and lysis is shown 
graphically in the form of a thromboelastogram [21]. The 
measured parameters include the K index  (a measure of 
platelet function), angle (a) which indicates the rate of fibrin-
formation, maximal amplitude (MA) reflecting the platelet 
contribution to clot formation and finally clot lysis, which 
is assessed at 30 and 60 min, and recorded as Lysis 30 and 
Lysis 60.
Rivaroxaban level
Rivaroxaban level in plasma samples will be measured using 
a specific chromogenic assay for anti-factor Xa activity with 
rivaroxaban calibrators by an investigator blinded to TEG 
and GTT results.
Additional measurements
Additionally, citrated plasma will be stored at − 80 °C for 
future analysis of factorial components of the fibrinolytic 
cascade (including, but not limited to plasminogen activa-
tor inhibitor-1, tissue plasminogen activator and thrombin 
activatable fibrinolysis inhibitor) and turbidimetric assay of 
fibrinolysis which assess plasma clot lysis.
In patients randomised to rivaroxaban, anti-Factor Xa 
levels will be checked to assess compliance and measure 
plasma activity of rivaroxaban [22].
Primary and secondary endpoints
The primary outcome measure is the change in fibrinolytic 
status as measured by Lysis Time (LT) using the GTT from 
admission to follow-up at 4 weeks post-discharge.
The secondary outcome measures are clinical events 
including re-intervention (further coronary angioplasty), 
major adverse cardiac events (composite of heart attack, 
stroke or death) and bleeding events evaluated by BARC 
criteria [23].
Statistical considerations
We aim to compare the effects of three different antithrom-
botic treatment strategies on endogenous fibrinolysis. The 
study will seek to evaluate the extent to which Very Low 
Dose Rivaroxaban (Group 2) reduces LT compared to Group 
1 and Group 3. Separate paired comparisons will be used 
to evaluate univariate effects between the study groups 
at 2 weeks, 4 weeks and 8 weeks. Similarly, the influ-
ence of Very Low Dose Rivaroxaban will be evaluated by 
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considering change over time from baseline using paired 
comparisons. Multivariable models (mixed models) will be 
used to estimate adjusted difference for baseline patient char-
acteristics, and to evaluate the influence of secondary varia-
bles on the treatment outcome. The effect of treatment group 
on major adverse cardiac events may be considered using 
Kaplan–Meyer, or Cox regression should sufficient events 
be determined to achieve reasonable power. Time to event is 
defined as the time from randomisation to the date of event 
and the censor date is defined as the last follow-up date for 
each participant i.e. 6 months from date of randomisation.
Sample size calculation
Sample size was calculated using Stata version 15.1 (Stat-
Corp, College Station, TX, USA). Assuming α = 0.05 for 
two sided tests, to detect a difference of LT = 90 s with a 
power 1 – β = 0.80, a sample size of 45 in each group would 
be required to detect a change in LT = 45 s. Accounting for 
a 10% drop-out, withdrawal and loss to follow up, we cal-
culated 50 patients in each group, resulting in a sample size 
of 150.
Ethical and regulatory aspects
The sponsor (East and North Hertfordshire NHS Trust, Ste-
venage, UK) has overall responsibility for the conduct of 
the study including assurance that the study is conducted 
in accordance to EU and international standards of Good 
Clinical Practice and International Conference on Harmo-
nisation guidelines, applicable government regulations and 
Ethics policies and procedures. The monitoring of the study 
will be done by University of Hertfordshire. A trial steering 
committee has been established and is responsible for over-
seeing the good execution and administrative progress of the 
protocol. The Data Safety Monitoring Board is responsible 
for periodically reviewing and evaluating the accumulated 
study data for participant safety, study conduct and progress, 
and making recommendations to the steering committee 
concerning the continuation, modification, or termination 
of the trial.
Status quo
The first patient in VaLiDate-R was enrolled in January 
2019. As per April 2019, a total of 65 patients were screened 
and 25 patients were randomised. Recruitment is currently 
ongoing with the aim of randomising the last patient by the 
February 2020 and completing the study with 6-month fol-
low up of the last patient by August 2020 and subsequent 
data lock.
Conclusions and outlook
Achieving improved net clinical benefit with current phar-
macological treatments of ACS have reached a plateau. 
Additional antithrombotic therapy in addition to antiplatelet 
therapy, in particular using Very Low Dose Rivaroxaban, 
has been shown to reduce adverse cardiovascular events but 
increase bleeding [9, 20].
Recent studies have identified impaired fibrinolysis in 
patients with ACS as a novel risk factor for recurrent adverse 
cardiovascular events, that is not affected by DAPT.
We propose to identify patients with ACS on DAPT who 
exhibit impaired fibrinolysis and assess whether the addition 
of Very Low Dose Rivaroxaban can favourably modify the 
fibrinolytic profile in these patients.
Through the VaLiDate-R study, we hope to (1) make use 
of a novel biomarker as a risk-stratification tool to identify 
patients who would benefit from more potent antithrombotic 
therapy and (2) assess the effect of additional low dose anti-
coagulation with rivaroxaban on endogenous fibrinolysis 
profile. If the addition of VLDR can bring about improve-
ment in endogenous fibrinolysis in patients with ACS, future 
large scale studies would be required to assess whether the 
beneficial effects of enhanced fibrinolysis through use of 
VLDR in patients with ACS and impaired fibrinolysis can 
translate into improved clinical outcomes, with reduction in 
major adverse cardiovascular events.
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